{"id":"ag-regimen","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, anemia, thrombocytopenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Cardiotoxicity (doxorubicin-related)"},{"rate":null,"effect":"Alopecia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The AG regimen combines two cytotoxic chemotherapy agents: adriamycin (doxorubicin), a topoisomerase II inhibitor that intercalates into DNA and causes strand breaks, and gemcitabine, a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA to disrupt replication. Together, these agents provide complementary mechanisms to maximize cancer cell death across multiple phases of the cell cycle.","oneSentence":"AG regimen is a chemotherapy combination regimen, typically consisting of adriamycin (doxorubicin) and gemcitabine, that works by damaging cancer cell DNA and inhibiting nucleotide synthesis to kill rapidly dividing cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:00:16.052Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Soft tissue sarcoma (Phase 3)"},{"name":"Other solid tumors (investigational)"}]},"trialDetails":[{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT06577441","phase":"PHASE2","title":"Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-12","conditions":"Myelodysplastic Syndrome","enrollment":54},{"nctId":"NCT06538623","phase":"PHASE2","title":"Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2024-08-23","conditions":"Pancreatic Neoplasms, Neoplasm Metastasis, Hepatic Metastasis of Pancreatic Cancer","enrollment":40},{"nctId":"NCT05444439","phase":"NA","title":"Antibiotyping and Prevalence of Virulent Genotypes Among Helicobacter Pylori and Their Impact on Response to Therapy","status":"COMPLETED","sponsor":"Assiut University","startDate":"2024-01-20","conditions":"H Pylori Infection","enrollment":100},{"nctId":"NCT07438106","phase":"PHASE2","title":"A Phase III Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-02","conditions":"Locally Advanced Pancreatic Cancer With KRAS G12D Mutation","enrollment":30},{"nctId":"NCT07415525","phase":"PHASE2","title":"IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang University","startDate":"2026-02-01","conditions":"Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma","enrollment":40},{"nctId":"NCT07408505","phase":"NA","title":"Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2026-01-20","conditions":"Advanced Pancreatic Ductal Adenocarcinoma, Cancer Anorexia-Cachexia Syndrome","enrollment":56},{"nctId":"NCT07240766","phase":"PHASE2","title":"HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2026-02-15","conditions":"Borderline Resectable Pancreatic Adenocarcinoma","enrollment":40},{"nctId":"NCT07312422","phase":"PHASE1, PHASE2","title":"LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study","status":"RECRUITING","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2025-09-30","conditions":"Pancreatic Cancer, PD-L1, PD-1 Inhibitor","enrollment":10},{"nctId":"NCT07362693","phase":"","title":"A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA","status":"NOT_YET_RECRUITING","sponsor":"Qianfoshan Hospital","startDate":"2025-12-31","conditions":"ABPA, Biologics, Allergic Bronchopulmonary Aspergillosis (ABPA)","enrollment":50},{"nctId":"NCT05327686","phase":"PHASE2","title":"Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-02-01","conditions":"Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8","enrollment":240},{"nctId":"NCT07328802","phase":"PHASE2","title":"Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01-01","conditions":"ORR,OS,PFS","enrollment":25},{"nctId":"NCT07110064","phase":"PHASE2","title":"QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Du Juan","startDate":"2025-09-03","conditions":"Advance Pancreatic Cancer","enrollment":80},{"nctId":"NCT07310069","phase":"PHASE2","title":"Gemcitabine and Nab-Paclitaxel Combined With Iparomlimab and Tuvorilimab for Advanced Gallbladder Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2025-05-01","conditions":"Gallbladder Cancer Unresectable","enrollment":44},{"nctId":"NCT07277452","phase":"PHASE2","title":"Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-12-10","conditions":"Pancreatic Cancer, Adult","enrollment":156},{"nctId":"NCT07262567","phase":"PHASE3","title":"Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","startDate":"2025-12","conditions":"Metastatic Pancreatic Cancer","enrollment":320},{"nctId":"NCT07231094","phase":"EARLY_PHASE1","title":"A Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy and Immunogenicity of a Tumor Vaccine Injection Targeting Stressinducible Proteins MICA/B in Combination With the AG Regimen in Patients With Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2025-11","conditions":"Pancreatic Cancer Metastatic","enrollment":13},{"nctId":"NCT05468489","phase":"PHASE3","title":"To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2022-11-18","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":200},{"nctId":"NCT06770439","phase":"PHASE2","title":"IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2025-04-18","conditions":"Advanced Pancreatic Cancers","enrollment":64},{"nctId":"NCT06770452","phase":"PHASE2","title":"HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2025-03-25","conditions":"Metastatic Pancreatic Carcinoma","enrollment":32},{"nctId":"NCT05821556","phase":"PHASE2","title":"Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2023-06-12","conditions":"Adenocarcinoma of the Pancreas","enrollment":240},{"nctId":"NCT07053150","phase":"PHASE2","title":"A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-15","conditions":"Advanced Digestive System Tumor","enrollment":80},{"nctId":"NCT06435260","phase":"PHASE2","title":"Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2024-08-01","conditions":"Pancreatic Cancer","enrollment":30},{"nctId":"NCT05078879","phase":"PHASE1","title":"Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-11-16","conditions":"Crohn's Disease, Glycogen Metabolism, Inflammatory Bowel Disease (IBD)","enrollment":4},{"nctId":"NCT06944106","phase":"PHASE2","title":"A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-03-28","conditions":"Pancreatic Cancer","enrollment":30},{"nctId":"NCT02577406","phase":"PHASE3","title":"An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation","status":"COMPLETED","sponsor":"Celgene","startDate":"2015-12-30","conditions":"Leukemia, Myeloid, Isocitrate Dehydrogenase","enrollment":319},{"nctId":"NCT05788094","phase":"PHASE4","title":"ACT vs CQ With Tafenoquine for P. Vivax Mono-infection","status":"RECRUITING","sponsor":"Shoklo Malaria Research Unit","startDate":"2023-06-26","conditions":"Malaria, Malaria, Vivax, Plasmodium Vivax Malaria","enrollment":606},{"nctId":"NCT03750669","phase":"PHASE3","title":"Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2018-10-20","conditions":"Pancreatic Adenocarcinoma Resectable, Neoadjuvant Chemotherapy","enrollment":324},{"nctId":"NCT06938503","phase":"PHASE2","title":"AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-04-21","conditions":"Pancreatic Cancer, Adult","enrollment":48},{"nctId":"NCT06916975","phase":"PHASE2","title":"Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jin Xu","startDate":"2025-04-15","conditions":"Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic","enrollment":46},{"nctId":"NCT06750861","phase":"PHASE2","title":"QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-02-15","conditions":"Pancreatic Adenocarcinoma","enrollment":30},{"nctId":"NCT06662669","phase":"PHASE1, PHASE2","title":"YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","startDate":"2024-11-30","conditions":"Metastatic Pancreatic Cancer","enrollment":120},{"nctId":"NCT06621095","phase":"PHASE2","title":"Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2024-10-30","conditions":"Pancreatic Cancer, First-line, Metastatic Pancreatic Cancer","enrollment":104},{"nctId":"NCT06573398","phase":"PHASE2","title":"Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-09-01","conditions":"Carcinoma, Pancreatic Ductal","enrollment":20},{"nctId":"NCT06454448","phase":"PHASE1, PHASE2","title":"Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-06-15","conditions":"Adebrelimab (SHR-1316), Decitabine, Metastatic Pancreatic Cancer","enrollment":20},{"nctId":"NCT05832892","phase":"PHASE1, PHASE2","title":"Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2023-11-01","conditions":"Unresectable Locally Advanced or Metastatic Pancreatic Cancer","enrollment":41},{"nctId":"NCT04438174","phase":"PHASE1, PHASE2","title":"Processed Amniotic Fluid (pAF) for the Treatment of Chronic Wounds","status":"TERMINATED","sponsor":"University of Utah","startDate":"2022-08","conditions":"Wounds and Injuries","enrollment":1},{"nctId":"NCT06404840","phase":"PHASE2","title":"Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-05-06","conditions":"Pancreatic Cancer","enrollment":30},{"nctId":"NCT06378580","phase":"","title":"The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma","status":"COMPLETED","sponsor":"Luo Cong","startDate":"2022-07-01","conditions":"Pancreatic Cancer","enrollment":72},{"nctId":"NCT06345599","phase":"PHASE1, PHASE2","title":"PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study)","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2024-05-01","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":66},{"nctId":"NCT04674956","phase":"PHASE3","title":"A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2021-03-04","conditions":"Pancreatic Cancer Stage IV, Pancreatic Cancer Metastatic","enrollment":401},{"nctId":"NCT04151277","phase":"PHASE2","title":"PRIMUS 001: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer","status":"UNKNOWN","sponsor":"Judith Dixon-Hughes","startDate":"2017-11-28","conditions":"Neoplasms Pancreatic","enrollment":500},{"nctId":"NCT06140082","phase":"","title":"Study on the Association of GSTP1 and Other Gene Polymorphisms With Platinum-induced Myelosuppression","status":"UNKNOWN","sponsor":"LI YAN","startDate":"2023-12-01","conditions":"Non-small Cell Lung Cancer","enrollment":477},{"nctId":"NCT05988372","phase":"PHASE2","title":"Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-10-23","conditions":"Locally Advanced Pancreatic Cancer","enrollment":50},{"nctId":"NCT06062485","phase":"PHASE2","title":"Surufatinib Combined With Toripalimab and AG Regiments for First-line Treatment of Unresectable or Relapsing Metastatic Ampullary Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2023-10","conditions":"Ampullary Carcinoma","enrollment":30},{"nctId":"NCT06051851","phase":"PHASE2","title":"Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2023-07-01","conditions":"Pancreatic Adenocarcinoma Metastatic","enrollment":177},{"nctId":"NCT05757336","phase":"PHASE2","title":"Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer","status":"RECRUITING","sponsor":"Lu Wang, MD, PhD","startDate":"2022-12-22","conditions":"Gallbladder Cancer, Initially Unresectable, the First Line Treatment","enrollment":50},{"nctId":"NCT05607134","phase":"NA","title":"Effect of Extracorporeal Shock Wave and Peripheral Magnetic Stimulation on Spastic CP Children","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2023-01-01","conditions":"Hemiplegic Cerebral Palsy","enrollment":45},{"nctId":"NCT05679050","phase":"PHASE2","title":"Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-10-01","conditions":"Resectable Pancreatic Cancer","enrollment":30},{"nctId":"NCT04176952","phase":"PHASE2","title":"PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer","status":"TERMINATED","sponsor":"Judith Dixon-Hughes","startDate":"2019-03-05","conditions":"Neoplasms Pancreatic","enrollment":31},{"nctId":"NCT05298020","phase":"PHASE2","title":"Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"The Affiliated Hospital of Xuzhou Medical University","startDate":"2022-04-01","conditions":"Advanced Pancreatic Cancer","enrollment":20},{"nctId":"NCT04617821","phase":"PHASE3","title":"AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-09-01","conditions":"Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma","enrollment":300},{"nctId":"NCT03037827","phase":"NA","title":"The Effect of Laser Power and Fiber Traction Speed on the Outcomes of Endovenous Laser Ablation","status":"COMPLETED","sponsor":"Clinic of Phlebology and Laser Surgery, Chelyabinsk, Russia","startDate":"2017-01-30","conditions":"Varicose Veins","enrollment":203},{"nctId":"NCT03292445","phase":"EARLY_PHASE1","title":"Inducing Graft Tolerance in HLA Haplotype Matched Related and 3 Ag Matched Unrelated Living Donor Kidney Transplantation","status":"UNKNOWN","sponsor":"Samuel Strober","startDate":"2017-02-14","conditions":"Immune Tolerance","enrollment":24},{"nctId":"NCT04268927","phase":"PHASE2","title":"Extended Letrozole Regimen Co-treatment With Gonadotropin Releasing Hormone Antagonist Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in Poor Responders Undergoing IVF-ET","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2018-04-01","conditions":"Infertility","enrollment":106},{"nctId":"NCT04101929","phase":"PHASE2","title":"Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2019-10-01","conditions":"Metastatic Pancreatic Cancer","enrollment":126},{"nctId":"NCT04089605","phase":"PHASE4","title":"Ranibizumab vs Dexamethasone Implant in Vitrectomized Eyes With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Far Eastern Memorial Hospital","startDate":"2017-06-01","conditions":"Diabetic Macular Edema","enrollment":48},{"nctId":"NCT03633734","phase":"PHASE1, PHASE2","title":"Efficacy Evaluation of Sequential Treatment With AG and Modified Folfirinox in Metastatic Pancreatic Adenocarcinoma","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2018-07-01","conditions":"Pancreatic Adenocarcinoma Metastatic, Chemotherapy Effect","enrollment":49},{"nctId":"NCT00106964","phase":"PHASE4","title":"Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2004-01","conditions":"HIV Infection, Hepatitis B","enrollment":371},{"nctId":"NCT00859222","phase":"PHASE1, PHASE2","title":"LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma","status":"COMPLETED","sponsor":"Patrick Y. Wen, MD","startDate":"2009-03","conditions":"Malignant Glioma","enrollment":51},{"nctId":"NCT01907139","phase":"NA","title":"Comparative Efficacy Research of Robot-Assisted Therapy With and Without Constraint-Induced Therapy in Stroke Rehabilitation","status":"COMPLETED","sponsor":"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","startDate":"2013-08","conditions":"Cerebrovascular Accident","enrollment":46},{"nctId":"NCT01655407","phase":"PHASE2","title":"Safety and Efficacy Study of Autologous Engineered Skin Substitute to Treat Partial- and Full-Thickness Burn Wounds","status":"UNKNOWN","sponsor":"Amarantus BioScience Holdings, Inc.","startDate":"2016-09","conditions":"Thermal Injury, Deep Partial-Thickness Burn, Full-Thickness Burn","enrollment":10},{"nctId":"NCT00746551","phase":"PHASE4","title":"Intravenous Versus Oral Iron in Late Pregnancy: Results of Treatment","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2008-09","conditions":"Anemia, Pregnancy Complications","enrollment":80},{"nctId":"NCT01948804","phase":"PHASE4","title":"The Comparison of Effect of Four Different Treatment Protocols on IVF Outcomes in Poor Responders Undergoing in Vitro Fertilization.","status":"UNKNOWN","sponsor":"Pınar Özcan Cenksoy","startDate":"2014-01","conditions":"Poor Responders Undergoing IVF","enrollment":100},{"nctId":"NCT01727648","phase":"NA","title":"Effects of RAT in Sequential Combination With CIT in Stroke Rehabilitation","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2012-08","conditions":"Cerebrovascular Accident","enrollment":92},{"nctId":"NCT01752153","phase":"PHASE1","title":"Immunomodulatory Effects of Silymarin in Patients With Beta-Thalassemia Major","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2012-06","conditions":"Immune Abnormalities","enrollment":25},{"nctId":"NCT01232075","phase":"PHASE2","title":"Extended Letrozole Regimen Versus Clomiphene Citrate for Superovulation in Patients With Unexplained Infertility Undergoing Intrauterine Insemination","status":"COMPLETED","sponsor":"Cairo University","startDate":"2008-09","conditions":"Infertility","enrollment":214},{"nctId":"NCT01219153","phase":"PHASE2","title":"Extended High Dose Letrozole Regimen Versus Short Low Dose Letrozole Regimen as an Adjuvant to GnRH Antagonist Protocol in the Management of Poor Responders Undergoing IVF-ET","status":"COMPLETED","sponsor":"Cairo University","startDate":"2008-09","conditions":"Infertility","enrollment":136},{"nctId":"NCT00774280","phase":"PHASE3","title":"Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning Regimen","status":"COMPLETED","sponsor":"Cooperative Study Group A for Hematology","startDate":"2002-05","conditions":"Leukemia, Myelodysplastic Syndrome","enrollment":130}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nab-paclitaxel and Gemcitabine"],"phase":"phase_3","status":"active","brandName":"AG regimen","genericName":"AG regimen","companyName":"Tianjin Medical University Cancer Institute and Hospital","companyId":"tianjin-medical-university-cancer-institute-and-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AG regimen is a chemotherapy combination regimen, typically consisting of adriamycin (doxorubicin) and gemcitabine, that works by damaging cancer cell DNA and inhibiting nucleotide synthesis to kill rapidly dividing cells. Used for Soft tissue sarcoma (Phase 3), Other solid tumors (investigational).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}